carboplatin

(redirected from Paraplatin)
Also found in: Medical.

carboplatin

[¦kär·bō′plat·ən]
(medicine)
A platinum coordination compound and anticancer agent used for advanced gynecologic malignancies, especially ovarian tumors, and for head and neck cancers and lung cancers.
References in periodicals archive ?
Drug Brand Names Carbamazepine * Carbatrol, Gemcitabine injection Tegretol * Gemzar Carboplatin * Paraplatin Lithium * Eskalith, Lithobid Divalproex sodium * Olanzapine * Zyprexa Depakote Paditaxel injection Doxorubicin liposome * Abraxane injection * Doxil Quetiapine * Seroquel Bottom Line
[29] That study showed that after adjuvant anthracycline treatment, weekly paclitaxel 80 mg/[m.sup.2] (And every 4 weekly paraplatin AUC5) seems less toxic and more efficient compared with 3 weekly paclitaxel 175 mg/[m.sup.2] (And paraplatin AUC5 every 3 weeks).
Ltd, Taichung, Taiwan, ROC) and carboplatin (area under curve = 6, Paraplatin, Bristol-Myers Squibb S.
yielded in March 1989, approving Paraplatin (carboplatin), a second
Lucidi was also worldwide vice president Virology & Oncology at Johnson & Johnson, where he led portfolio strategy from drug discovery to market and served in senior leadership at Bristol-Myers Squibb, where he was responsible for the strategy and launch of several new antiviral and oncology products, includingVidex (didanosine), Zerit (stavudine), Paraplatin (carboplatin) andTaxol (paclitaxel).
He was worldwide vice-president virology & oncology at Johnson & Johnson where he led portfolio strategy from drug discovery to market, and served in senior leadership at Bristol-Myers Squibb where he was responsible for the strategy and launch of several new antiviral and oncology products, including but not limited to Videx (didanosine), Zerit (stavudine), Paraplatin (carboplatin) and Taxol (paclitaxel).
In 2014, the drug bevacizumab (Avastin) was approved for treating recurrent cervical cancer and ovarian cancer that are resistant to platinum-based anticancer agents, such as cisplatin (Paraplatin) and carboplatin (Platinol).
For non-small-cell lung cancer, the most common combinations include the use of carboplatin (Paraplatin) or cisplatin (Platinol), in combination with a second drug.
Chemotherapy treatment commonly centers on platinum drugs, such as cisplatin (Platinol[R]) and paraplatin (Carboplatin[R]).
For non-small cell lung cancer, national guidelines call for the use of carboplatin (Paraplatin) and/or cisplatin (Platinol), in combination with a second drug.
The other drugs reviewed that also had no new safety concerns were anti-neoplastic agent Camptosar (irinotecan), antineoplastic agent Paraplatin (carboplatin), platelet-reducing agent Agrylin (anagrelide), and hematinic agent Ferrlecit (sodium ferric gluconate complex).
The other drugs reviewed that also had no new safety concerns were antineoplastic agent irinotecan (Camptosar), antineoplastic agent carboplatin (Paraplatin), platelet-reducing agent anagrelide (Agrylin), and hematinic agent sodium ferric gluconate complex (Ferrclecit).